Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 191

1.

Obesity, prostate-specific antigen nadir, and biochemical recurrence after radical prostatectomy: biology or technique? Results from the SEARCH database.

Ho T, Gerber L, Aronson WJ, Terris MK, Presti JC, Kane CJ, Amling CL, Freedland SJ.

Eur Urol. 2012 Nov;62(5):910-6. doi: 10.1016/j.eururo.2012.08.015. Epub 2012 Aug 20.

PMID:
22921964
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Definition and preoperative predictors of persistently elevated prostate-specific antigen after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.

Moreira DM, Presti JC Jr, Aronson WJ, Terris MK, Kane CJ, Amling CL, Freedland SJ.

BJU Int. 2010 Jun;105(11):1541-7. doi: 10.1111/j.1464-410X.2009.09016.x. Epub 2009 Nov 12.

PMID:
19912191
[PubMed - indexed for MEDLINE]
3.

Parameters derived from the postoperative decline in ultrasensitive PSA improve the prediction of radical prostatectomy outcome.

Vesely S, Jarolim L, Schmidt M, Minarik I, Dusek P, Babjuk M.

World J Urol. 2013 Apr;31(2):299-304. doi: 10.1007/s00345-012-0892-3. Epub 2012 Jun 10.

PMID:
22684375
[PubMed - indexed for MEDLINE]
4.

Obesity and oncological outcome after radical prostatectomy: impact of prostate-specific antigen-based prostate cancer screening: results from the Shared Equal Access Regional Cancer Hospital and Duke Prostate Center databases.

Freedland SJ, Sun L, Kane CJ, Presti JC Jr, Terris MK, Amling CL, Moul JW, Aronson WJ.

BJU Int. 2008 Sep;102(8):969-74. doi: 10.1111/j.1464-410X.2008.07934.x. Epub 2008 Aug 7.

PMID:
18691175
[PubMed - indexed for MEDLINE]
5.

Three-year postoperative ultrasensitive prostate-specific antigen following open radical retropubic prostatectomy is a predictor for delayed biochemical recurrence.

Malik RD, Goldberg JD, Hochman T, Lepor H.

Eur Urol. 2011 Sep;60(3):548-53. doi: 10.1016/j.eururo.2011.05.036. Epub 2011 May 26.

PMID:
21652145
[PubMed - indexed for MEDLINE]
6.

Detectable prostate-specific antigen Nadir during androgen-deprivation therapy predicts adverse prostate cancer-specific outcomes: results from the SEARCH database.

Keto CJ, Aronson WJ, Terris MK, Presti JC, Kane CJ, Amling CL, Freedland SJ.

Eur Urol. 2014 Mar;65(3):620-7. doi: 10.1016/j.eururo.2012.11.052. Epub 2012 Dec 6.

PMID:
23245686
[PubMed - indexed for MEDLINE]
7.

Diabetes predicts metastasis after radical prostatectomy in obese men: results from the SEARCH database.

Wu C, Aronson WJ, Terris MK, Presti JC Jr, Kane CJ, Amling CL, Freedland SJ.

BJU Int. 2013 Jun;111(8):E310-8. doi: 10.1111/j.1464-410X.2012.11687.x. Epub 2013 Jan 10.

PMID:
23305170
[PubMed - indexed for MEDLINE]
8.

Obesity and biochemical outcome following radical prostatectomy for organ confined disease with negative surgical margins.

Freedland SJ, Terris MK, Presti JC Jr, Amling CL, Kane CJ, Trock B, Aronson WJ; Search Database Study Group.

J Urol. 2004 Aug;172(2):520-4.

PMID:
15247719
[PubMed - indexed for MEDLINE]
9.

Obesity is associated with castration-resistant disease and metastasis in men treated with androgen deprivation therapy after radical prostatectomy: results from the SEARCH database.

Keto CJ, Aronson WJ, Terris MK, Presti JC, Kane CJ, Amling CL, Freedland SJ.

BJU Int. 2012 Aug;110(4):492-8. doi: 10.1111/j.1464-410X.2011.10754.x. Epub 2011 Nov 17.

PMID:
22094083
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Postoperative prostate-specific antigen nadir improves accuracy for predicting biochemical recurrence after radical prostatectomy: Results from the Shared Equal Access Regional Cancer Hospital (SEARCH) and Duke Prostate Center databases.

Moreira DM, Presti JC Jr, Aronson WJ, Terris MK, Kane CJ, Amling CL, Sun LL, Moul JW, Freedland SJ.

Int J Urol. 2010 Nov;17(11):914-22. doi: 10.1111/j.1442-2042.2010.02631.x. Epub 2010 Sep 30.

PMID:
20880361
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Pelvic/retroperitoneal salvage lymph node dissection for patients treated with radical prostatectomy with biochemical recurrence and nodal recurrence detected by [11C]choline positron emission tomography/computed tomography.

Rigatti P, Suardi N, Briganti A, Da Pozzo LF, Tutolo M, Villa L, Gallina A, Capitanio U, Abdollah F, Scattoni V, Colombo R, Freschi M, Picchio M, Messa C, Guazzoni G, Montorsi F.

Eur Urol. 2011 Nov;60(5):935-43. doi: 10.1016/j.eururo.2011.07.060. Epub 2011 Aug 3.

PMID:
21840116
[PubMed - indexed for MEDLINE]
13.

Obesity as a predictor of adverse outcome across black and white race: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) Database.

Jayachandran J, Bañez LL, Aronson WJ, Terris MK, Presti JC Jr, Amling CL, Kane CJ, Freedland SJ; SEARCH Database Study Group.

Cancer. 2009 Nov 15;115(22):5263-71. doi: 10.1002/cncr.24571.

PMID:
19670453
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Ultrasensitive serum prostate specific antigen nadir accurately predicts the risk of early relapse after radical prostatectomy.

Shen S, Lepor H, Yaffee R, Taneja SS.

J Urol. 2005 Mar;173(3):777-80.

PMID:
15711268
[PubMed - indexed for MEDLINE]
15.

Biochemical recurrence after robot-assisted radical prostatectomy in a European single-centre cohort with a minimum follow-up time of 5 years.

Sooriakumaran P, Haendler L, Nyberg T, Gronberg H, Nilsson A, Carlsson S, Hosseini A, Adding C, Jonsson M, Ploumidis A, Egevad L, Steineck G, Wiklund P.

Eur Urol. 2012 Nov;62(5):768-74. doi: 10.1016/j.eururo.2012.05.024. Epub 2012 May 18.

PMID:
22633365
[PubMed - indexed for MEDLINE]
16.

Survival following biochemical recurrence after radical prostatectomy and adjuvant radiotherapy in patients with prostate cancer: the impact of competing causes of mortality and patient stratification.

Abdollah F, Boorjian S, Cozzarini C, Suardi N, Sun M, Fiorino C, di Muzio N, Karakiewicz PI, Montorsi F, Karnes RJ, Briganti A.

Eur Urol. 2013 Oct;64(4):557-64. doi: 10.1016/j.eururo.2013.03.006. Epub 2013 Mar 13.

PMID:
23506833
[PubMed - indexed for MEDLINE]
17.

Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.

Ploussard G, Agamy MA, Alenda O, Allory Y, Mouracade P, Vordos D, Hoznek A, Abbou CC, de la Taille A, Salomon L.

BJU Int. 2011 Jun;107(11):1748-54. doi: 10.1111/j.1464-410X.2010.09728.x. Epub 2010 Sep 30.

PMID:
20883488
[PubMed - indexed for MEDLINE]
18.

Dutasteride treatment over 2 years delays prostate-specific antigen progression in patients with biochemical failure after radical therapy for prostate cancer: results from the randomised, placebo-controlled Avodart After Radical Therapy for Prostate Cancer Study (ARTS).

Schröder F, Bangma C, Angulo JC, Alcaraz A, Colombel M, McNicholas T, Tammela TL, Nandy I, Castro R.

Eur Urol. 2013 May;63(5):779-87. doi: 10.1016/j.eururo.2012.11.006. Epub 2012 Nov 12.

PMID:
23176897
[PubMed - indexed for MEDLINE]
19.

Comparison of percentage of total prostate needle biopsy tissue with cancer to percentage of cores with cancer for predicting PSA recurrence after radical prostatectomy: results from the SEARCH database.

Freedland SJ, Aronson WJ, Csathy GS, Kane CJ, Amling CL, Presti JC Jr, Dorey F, Terris MK; SEARCH Database Study Group.

Urology. 2003 Apr;61(4):742-7.

PMID:
12670558
[PubMed - indexed for MEDLINE]
20.

Prognostic implications of an undetectable ultrasensitive prostate-specific antigen level after radical prostatectomy.

Eisenberg ML, Davies BJ, Cooperberg MR, Cowan JE, Carroll PR.

Eur Urol. 2010 Apr;57(4):622-9. doi: 10.1016/j.eururo.2009.03.077. Epub 2009 Apr 3.

PMID:
19375843
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk